An interventional study of Remote Programming and Standard Programming in Deep Brain Stimulation, Telemedicine and Parkinson Disease, sponsored by Thomas Köglsperger. Completed at 1 site in Germany. Open to participants aged 35 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-08-29.
Sponsored by Thomas Köglsperger · Not applicable, Interventional, and Treatment
Deep brain stimulation (DBS) represents the treatment of choice for advanced stages of Parkinson's disease (PD). Currently, adaptive closed-loop stimulation systems that apply disease-specific biomarkers, such as local field potentials (LFPs), are being actively examined to facilitate DBS programming. However, the most suitable feedback signal, still remains to be determined. The investigators previously tested the usefulness of the patient's subjective rating on a visual analogue scale (VAS) as a potential feedback signal for DBS adjustment and found that VAS-based programming lead to similar results as our standard approach. One of the practical advantages of using VAS-based programming strategies - in addition to saving time - is the principal applicability of such an approach to a remote programming setting, although a validation of such an approach is required. Within the scope of a prospective, randomized multicenter clinical trial (the REMOTE Trial), the investigators will examine the effectiveness and safety of VAS-based remote DBS programming in PD by using a novel and recently introduced software platform (Abbott NeurosphereTM Virtual Clinic) that allows for the programming through a smartphone-based video connection with the patient. Therefore, n = 50 PD patients undergoing STN-DBS surgery will be randomized and subsequent to surgery will have their IPG settings adjusted either during regular visits at the hospital or alternatively be programmed remotely through a VAS-based approach. Prior to surgery and after a 90 days follow-up period, we will assess specific clinical (MDS-Unified Parkinson's Disease Rating Scale = UPDRS, Parkinson's Disease Questionnaire-39 sum index = PDQ-39 SI, Beck Depression Inventory = BDI, Montreal Cognitive Assessment Scale = MOCA) parameters to determine the effectivity and safety of the two different strategies on the patient outcome and to correlate it with VAS ratings and MRI data. The results will support the examination of remote-based DBS programming and evaluate the patient's subjective judgment as a valid feedback signal.
4,487 studies on the registry are indexed under Parkinson Disease; 1,082 are open to participants now.
This study's enrollment of 54 is above the median of 40 across 3,294 interventional studies indexed under Parkinson Disease.
Browse Parkinson Disease studies →This is the only study on the registry with Thomas Köglsperger as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Patients in Group A (active comparator) will have their internal pulse generator (IPG) adjusted by conventional procedures, i.e. by regular visits at their caregivers hospital.
Device: Standard Programming
Patients in Group B (experimental) will have their internal pulse generator (IPG) adjusted by using a novel software (Abbot NeurosphereTM Virtual Clinics) that allows for remote IPG programming and with the aid of a visual analogue scale (VAS).
Device: Remote Programming
Patients in the experimental group (Group B) will have their internal pulse generators (IPGs) adjusted through a novel software that allows for remote DBS programming (NeurosphereTM Virtual Clinic)
Patients in the active comparator group (Group A) will have their internal pulse generators (IPGs) adjusted through a standard procedure at their caregivers institution.
Change in UPDRS-III (Stimulation ON/Medication ON = STIM-ON/MED-ON)
Part III of the MDS-Unified Parkinson's Disease Rating Scale (Range 0-128 pts. with high values indicating a more severe disease symptoms)
Time frame: Assessed at Day 90
Change in UPDRS-I
Part I of the MDS-Parkinson's Disease Rating Scale (Range 0-52 pts. with high values indicating more severe disease symptoms)
Time frame: Assessed at day -1 and +90 (day 0 = implantation of DBS electrodes)
Change in UPDRS-II
Part II of the MDS-Parkinson's Disease Rating Scale (Range 0-52 pts. with high values indicating more severe disease symptoms)
Time frame: Assessed at day -1 and +90 (day 0 = implantation of DBS electrodes)
Change in UPDRS-IV
Part IV of the MDS-Parkinson's Disease Rating Scale (Range 0-24 pts. with high values indicating more severe disease symptoms)
Time frame: Assessed at day -1 and +90 (day 0 = implantation of DBS electrodes)
Change in PDQ-39-SI
Parkinson's Disease Questionnaire-39 Sum Index (Range 0-100 pts. with high values indicating more severe disease symptoms)
Time frame: Assessed at day -1 and +90 (day 0 = implantation of DBS electrodes)
Change in Patient Rating (Patient Diary)
Number of hours spent with bothersome dyskinesia or in a reduced mobility state (OFF)
Time frame: Assessed on a weekly basis by the patient between day +5 and +90 (day 0 = implantation of DBS electrodes)
Number of visits at the the hospital or remotely
Number of doctor-patient contacts either in person at the hospital (Group A) or remotely (Group B)
Time frame: Assessed at day +90 (day 0 = implantation of DBS electrodes)
Change in TEED
Total Electrical Energy Delivered by the IPG; TEED (1s) = (voltage2 × frequency × pulsewidth) / impedance (1s)
Time frame: Assessed at day +5 and +90 (day 0 = implantation of DBS electrodes)
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.